Alamar Biosciences, Inc.
ALMR
$21.25
$1.055.17%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Net Income | -178.43% | ||||
| Total Depreciation and Amortization | 31.42% | ||||
| Total Amortization of Deferred Charges | 59.52% | ||||
| Total Other Non-Cash Items | 1,439.70% | ||||
| Change in Net Operating Assets | -61.26% | ||||
| Cash from Operations | -55.70% | ||||
| Capital Expenditure | -8.30% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -101.01% | ||||
| Cash from Investing | -104.57% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | 641.98% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -- | ||||
| Cash from Financing | 22,846.91% | ||||
| Foreign Exchange rate Adjustments | -139.10% | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 699.45% | ||||